Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease, with its lead program ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...